

Lisa Sullivan

Lisa Sullivan is the **Associate Dean for Education at the School of Public Health**. She has a PhD in Statistics and is Professor of Biostatistics and former Chair of the Department of Biostatistics. She teaches Biostatistics for MPH students and was instrumental in developing a minor program in public health which is open to undergraduate students at Boston University. She is Principal Investigator of the Summer Institute for Training in Biostatistics which is designed to promote interest in the field of biostatistics and its many exciting career opportunities. Lisa is co-author of a textbook entitled *Introductory Applied Biostatistics*, author of *Essentials of Biostatistics in Public Health* (currently in its second edition) and Editor-in-Chief of the *Encyclopedia of Clinical Trials*. She is the recipient of numerous teaching awards for excellence in teaching. Lisa is a senior statistician on the Framingham Heart Study working primarily in developing and disseminating cardiovascular risk functions. She is active in multidisciplinary research projects including a variety of projects in cardiovascular disease, a large epidemiological study to assess the association between alcohol exposure in pregnancy and sudden infant death syndrome (SIDS), studies to improve methods for prenatal diagnosis and a clinical trial to improve repetitive behaviors in children affected with autism.

Other Positions:

- Associate Dean for Education, Boston University School of Public Health
- Associate Professor, Clinical Epi Research & Training, Medicine, Boston University School of Medicine
- Boston Medical Center

Cherrie Butts

Dr. Butts is **Associate Director of Program Leadership at Biogen** (Cambridge, MA). She obtained undergraduate and master's degrees from The Johns Hopkins University. Her pre-doctoral studies at the University of Texas Health Science Center – Houston/UT MD Anderson Cancer Center characterized anti-tumor immune responses in patients with ovarian cancer. Her postdoctoral studies at the National Institutes of Health examined regulation of immunity by neuroendocrine factors. She continued this work at the US Food & Drug Administration and took on responsibilities of evaluating drug and biologics applications. She moved to New England for a project management position at Biogen. In this role, she manages the Research portfolio and works with teams to facilitate project progress, make critical decisions, and mitigate risk. She is also very passionate about ensuring the scientific community appreciates contributions of individuals from all backgrounds. She does so by working with scientific organizations to foster communication and transform perceptions of underrepresented scientists.

Marisa LaFleur

Marisa has been involved in publishing since beginning her degree in Publishing at Emerson College, where she held various editorial internships and assistantships. She joined the academic publishing world in 2012 and has worked at **Elsevier** since 2013, where she has been an **Editorial Project Manager** involved with Criminal Justice, Emergency Management, Food Science, and Earth and Environmental Science titles, and is now an **Associate Acquisitions Editor for Space and Planetary Science**.

She is particularly interested in utilizing technology to expand the reach and utility of books in the "Digital Age." Beyond Elsevier, Marisa enjoys assisting with author events at her local bookstore, exploring bike trails, and playing French horn in local community groups.

Katey Bircher

Katey has been in scholarly book publishing since 2005, working to develop high quality content to support and advance healthcare practice and scientific research. She cares deeply about issues for women in STEM and improving access to science education globally. Katey is also passionate about running, cooking, wine, travel, history, and literature.

Josh Lang

Josh, MBA, is currently an **account manager with Thermo Fisher Scientific**. He works directly with the Novartis Institute of Biomedical Research managing all of their laboratory service needs for their researchers. Josh is also the Director of Business Development for Biotech Tuesday, one of Boston's largest biotech networking organizations that caters to over 4,000 life science individuals. Through his role with Biotech Tuesday, he has organized events with numerous top tier biotech companies along with conferences such as Bio-IT and BIO. Josh also has an MBA from Northeastern University.

Cinzia Metallo

Cinzia Metallo, PhD currently works in the **Health Economics and Outcomes Research (HEOR) practice at Analysis Group, an economic, financial, and strategy consulting firm**. She is also the founder of Biomille Technologies, a medical device company based on a technology she developed during her PhD in Neuroscience at the Sackler School of Biomedical Sciences at Tufts University. In 2013, she won the Tufts \$100K Business Plan Competition. In 2014, she was selected to participate in MassChallenge, the world's largest startup accelerator, and other startup accelerators. Her academic background includes a Master's Degree in Physics from the University of Tennessee in Knoxville, TN. She also serves as a Mass AWIS board member and membership committee co-chair.

Abigail Lytton-Jean

Dr Abigail Lytton-Jean **leads the Peterson (1957) Nanotechnology Materials Core Facility in the Koch Institute for Integrative Cancer Research at MIT**. Abigail conducted her postdoctoral work in the Koch Institute with Professors Robert Langer and Daniel Anderson where she developed biodegradable nanoparticles for intracellular delivery of siRNA. Prior to joining the Koch Institute she did her PhD work with Professor Chad Mirkin at Northwestern University where she studied the fundamental properties of DNA-modified gold nanoparticles and used these materials to develop biological and chemical detection systems and harnessed the DNA binding properties to form self-assembled nanostructures. <https://ki.mit.edu/sbc/nanocore>

Gail Radcliffe

Gail E. Radcliffe, Ph.D. has more than 20 years experience assisting medical device and diagnostics companies with technical assessment, marketing and clinical/regulatory issues. Gail **founded Radcliffe Consulting** in 1998 after having worked at GENE-TRAK, where she developed IVD assays for several infectious disease organisms including HIV, CMV, TB and Chlamydia and was responsible for instituting the clinical affairs group. She later joined Cytoc Corporation where she identified novel applications for the ThinPrep Processor and helped forge partnerships with other health care companies to expand product offerings.

As a consultant, Gail has provided assistance to startup and established medical device companies with market research, regulatory strategy (IVD vs. CLIA lab) and submissions, quality systems development and clinical trial support. Consulting engagements have encompassed a wide range of products including cutting edge digital pathology instruments, stem cell laser dissection devices, companion diagnostics, and multiplex molecular, POC and CLIA Waived *in vitro* diagnostic devices.

Gail obtained a Ph.D. in Molecular Biology from Brown University and completed a postdoctoral fellowship in molecular immunology at the University of Massachusetts Medical School.

She is a member of the Regulatory Affairs Professional Society (RAPS), American Society of Microbiology (ASM) and Sigma Xi. She is on the Board of Trustees of the Massachusetts Biomedical Initiatives and acts as an advisor to venture capital companies.

Regina Au

Regina Au is a New **Product Planning/Strategic Commercial Consultant at BioMarketing Insight** with 20+ years experience in the biotechnology, pharmaceutical, medical device, diagnostic and healthcare industries. She helps companies to maximize the benefits of their technology upfront by conducting an in-depth business due diligence to de-risk the product development process and increase commercial success. This ensures that the technology is the right product for the right market in meeting a critical unmet need and that the market opportunity for the product meets the business goals of the company. She will translate these unmet needs into a product profile or specification. Ms. Au then develops marketing strategies to ensure product adoption and market access.

Prior to BioMarketing Insight she worked for companies such as Merck & Co., Genzyme Corp., NMT Medical, and Radi Medical (St. Jude Medical) in various positions of increasing responsibility in marketing and sales. She had P&L responsibility in managing a number of multimillion dollar product lines and has experience in upstream and downstream marketing including strategic marketing, product development, market development, product launches, and product management.

Her background includes an MBA in Marketing from the University of Connecticut, a Microbiology degree from the University of Michigan and a Masters in International Management from Thunderbird School of Global Management.

Oona Johnstone

Oona Johnstone, PhD is a **patent attorney at Wolf Greenfield** who focuses her practice on U.S. and foreign patent prosecution, IP due diligence, client counseling, and post-grant proceedings, including inter partes review (IPR), in the areas of biotechnology, pharmaceuticals and cleantech. Her expertise spans a wide range of technologies including RNA-based therapeutics, transgenics, antibodies, immune-modulating agents, metabolic engineering, systems and synthetic biology, and drug delivery. Prior to joining Wolf Greenfield, Oona was a postdoctoral researcher in the Department of Systems Biology at Harvard Medical School. She earned a Ph.D. in Biology from McGill University, where she authored and co-authored publications in journals including *Molecular Cell*, *Development*, *Developmental Biology*, *International Review of Cytology*, and *Annual Review of Genetics*.

Susanne Swalley

Susanne Swalley, PhD is an **Investigator in the Developmental and Molecular Pathways department at the Novartis Institutes for Biomedical Research**. Trained as a chemist, her current research focuses on biochemical and biophysical approaches to target identification. Prior to Novartis, she was a scientist at Vertex Pharmaceuticals where she contributed to a wide variety of project teams on the evaluation and screening of new targets. Susanne graduated from Amherst College with bachelor's degrees in chemistry and music, and obtained a Ph.D. in chemistry from the California Institute of Technology with Dr. Peter Dervan. She completed her postdoctoral training at Harvard University in the laboratories of Dr. Don Wiley and Dr. Stephen Harrison with fellowships from the Damon Runyon-Walter Winchell Cancer Research Fund and the Charles A. King Trust.

Mark N. Milton

Mark Milton, PhD is an **Executive Director at Novartis**. He has 25 years' experience in the pharmaceutical industry, working on the development of small molecule drugs and biotherapeutics for companies large and small. Mark was educated in the UK, receiving a B.Sc. in Biochemistry and Soil Science from UCNW, Bangor in 1982, a M.Sc. in Toxicology and PhD in Biochemical Toxicology from the University of Surrey. Mark moved to the University of Illinois at Champaign-Urbana for post-doctoral research before joining the pharmaceutical industry. After a decade at G.D. Searle in Chicago, he moved to Cambridge to join Millennium Pharmaceuticals and subsequently moved to a nanotechnology company, Tempo Pharmaceuticals. In 2009, he joined Novartis where he provides nonclinical and clinical PKPD support to the development of biologics (antibodies, therapeutic proteins, Gene therapy and Cell Therapy products)predominantly to treat Ocular diseases. Mark has been involved in leadership positions in several industry associations, has been a member of the organizing committee for several conferences and has published and presented extensively on the DMPK aspects of the development of both NCEs and Biologics.

Kristina Kapinas

Kristie is currently a **Medical Science Liaison for Vertex Pharmaceuticals** in the Northeast US, responsible for disease education. She is originally from Pennsylvania, where she first became interested in science as a competitor in Science Olympiad. She received her B.S. in Biochemistry/Biophysics and Biology from Rensselaer Polytechnic Institute, where she first became involved in research, specifically in oncology. She received her Ph.D. in Biomedical Sciences and Cell Biology from the University of Connecticut Health Center, where she focused on the molecular mechanisms of bone formation and osteoporosis. Prior to leaving academia, she completed her postdoctoral training in two labs at the University of Massachusetts Medical School, identifying mechanisms of embryonic stem cell pluripotency and differentiation. Kristie has been an active member and volunteer of MASS AWIS since transplanting to MA, and looks forward to an amazing 2016 as a Board member!

Raulina Wojtkiewicz

Raulina Wojtkiewicz is a **Manager and a Senior Engineer in AIR's Research and Modeling group**, where she is responsible for developing and enhancing the vulnerability component of AIR's detailed flood models for the United States, Europe and Japan. Prior to joining AIR, Raulina was a Research Assistant at Northeastern University, where she received her M.S. in Civil and Structural Engineering. Her research focused on the study of flow-induced vibration and fluid-

structure interaction of long-span bridges. She completed her undergraduate work at Pontificia Universidad Católica Madre y Maestra (PUCMM) in Santiago, Dominican Republic.

Cecilia Scimia

Dr. Scimia is a Cardiologist, and PhD in Molecular Medicine that is pursuing the passion and the desire to contribute to the advancement of Medicine and Innovation. After having obtained clinical training in Cardiology, Cecilia left Italy to be trained as a Scientist and went to UCSD and Sanford-Burnham for Medical research in San Diego. Her research thesis elucidated mechanisms underlying heart failure and culminated in a first author publication in Nature. Subsequently she moved to Philadelphia to pursue a Physician-Scientist career at Temple University. During this period she became interested in combining Innovation and Entrepreneurship with Medicine and Science and earned a Master Degree in Management, Innovation and Entrepreneurship at Fox School of Business in Philadelphia and started her own company based on a cardiac medical device that she invented (CardioCorp LLC). Since August 2015 she has left Academia and has started working in **Medical Affairs at Takeda Pharmaceuticals as a Medical Science Liaison**.

Stanley O. King

Stan is the **Senior Director of Business Development at Emulate Inc.** Prior to joining Emulate, he worked in business development and licensing roles at Boston Children's Hospital's Technology Innovation and Development Office, the Wyss Institute for Biologically Inspired Engineering at Harvard, the MIT Technology Licensing Office, and UVa Innovation. He's managed intellectual property, developed licensing strategies, and executed deals for a wide variety of life science technologies, all with the goal of commercializing early-stage research discoveries. In addition, he worked internationally with a non-governmental organization developing strategies to foster an entrepreneurship ecosystem in Rwanda. Stan has a B.S. from Florida A & M University and obtained his Ph.D. in Neuroscience from the University of Virginia.

Marcy Patrick

Marcy Patrick received her Ph.D. in Microbiology and Immunology from the University of Michigan in 2011. Currently she works as a **Senior Scientist at Addgene**, a mission driven, nonprofit biorepository dedicated to helping scientists around the world share plasmid reagents. Although no longer at the bench, her position keeps her up-to-date with diverse scientific technologies and research, and allows her to interact with scientists of all levels and disciplines worldwide.

Phyllis Ottaviano

Phyllis Ottaviano received her Ph.D. in the dual Molecular Medicine/Cell and Molecular Biology programs from Boston University School of Medicine. During her graduate work she studied the role of a key extracellular antioxidant selenoprotein in thrombosis and stroke. She then went on to do a Research Fellowship at Beth Israel Deaconess Medical Center/Harvard Medical School in cardiac hypertrophy and heart failure. Phyllis is a scientist with extensive Drug Discovery Research and Development experience in both the biotech and pharmaceutical settings which includes working with biologics and small molecules. She currently works at **Forma Therapeutics** as a **Scientist in Research Discovery**. Her role focuses on working with small molecules in a therapeutic discovery setting by developing and designing the subsequent functional cell-based assays toward the selection of oncology disease candidates. She also examines the disease

biomarker from target engagement to PD efficacy studies. Phyllis' hobbies include indoor-rock climbing, dance, and travel. She is also an active member and volunteer AWIS and WEST.

Justin Goedde

Justin Goedde is a **Human Resources Generalist at Idera Pharmaceuticals**. In his role, Justin manages a wide range of human resources functions including recruiting and onboarding, benefits plan administration and talent management. Justin's professional experience has spanned many industries including life sciences, software and retail. This diverse background has helped Justin to better understand the role HR plays in driving any successful business strategy. To Justin, the most rewarding part of working in HR is helping employees be successful in their jobs and seeing that individual success reflected in the success of the organization.

Sandeep Menon

Dr. Sandeep Menon is currently the **Vice President and Head of Statistical Research and Consulting Center at Pfizer Inc.** and also holds **Adjunct faculty positions at Boston University and Tufts University School of Medicine**. His research interests are in adaptive designs and personalized medicine. His group globally provides scientific and statistical leadership and provides consultation to the Global Head of Statistics, senior Pfizer management in Discovery, Clinical Development, Legal, Commercial and Marketing. His responsibilities also include providing a strong presence for Pfizer in regulatory and professional circles to influence content of regulatory guidelines and their interpretation in practice. He is a core member of the Pfizer Global Clinical Triad (Biostatistics, Clinical and Clinical Pharmacology) Leadership team. He has been in the industry for over a decade and prior to joining Pfizer he worked at Biogen Idec and Aptiv Solutions.

Sandeep received his Medical degree from the University of Bangalore (formerly Karnataka University), India and later completed his Masters and PhD in Biostatistics at Boston University and was a research fellow at Harvard Clinical Research Institute. He has received several awards for academic and research excellence.

Arriana Harris

Ariana Harris-received her Ph.D. in Molecular Medicine from Boston University School of Medicine after earning a B.S. in Microbiology from the University of Rhode Island. She currently works at **Nelson Mullins Riley & Scarborough, LLP as a Technical Specialist** in the Biotechnology group and is attending Suffolk University Law School. She works with several partners and associates in drafting and prosecuting US and foreign patent applications.

Paul Wasserzieher

Paul Wasserzieher is **QA Specialist at Amgen, Inc.** with over 10 years of experience in the biotech industry. Paul leads the investigation process (including report writing) for nonconformances at the Amgen commercial drug product facility in Woburn, MA. His background is a BA in Chemical Engineering from Michigan Technological University. He spent the first 5 years of his career in the agricultural industry supporting Canola oil and Xanthan Gum manufacturing facilities. The last 12 years of his career has been with Amgen, supporting commercial manufacturing of biologic drugs such as Erythropoietin, Enbrel and Imlygic. Within the last year he has transitioned from Engineering into the Quality department to his current role as a Lead Investigator. Paul's career path to QA has been atypical, as most in QA do not have an engineering background. In his current role at Amgen, he works closely with regulatory and compliance agencies such as the FDA.

Lisa Welch

Lisa Welch is the **Director of Organizational Development for DynaMed**, an evidence-based medical database that provides answers to questions clinicians face at the point-of-care. Over the past 10 years at DynaMed, she has worked in various capacities, including as a Medical Writer, Medical Editor and Managing Editor. Lisa began her career as a research technician at the VA hospital in Boston, conducting research on post-traumatic stress disorder in women veterans. She has experience in writing grant proposals, IRB compliance and critical appraisal of research, as well as team development and management. Lisa completed her undergraduate degree at Rice University in Houston, TX and earned a MSc in Health Communications from Boston University.